NCT06435442View on ClinicalTrials.gov

PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers

PHASE1Enrolling by invitationINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions

Healthy

Interventions

DRUG

Epaminurad, Naproxen

Period 1: Epaminurad 6mg -\> Epaminurad 9mg -\> Epaminurad 9mg +Naproxen Period 2: Naproxen

DRUG

Epaminurad

Epaminurad

DRUG

Epaminurad placebo

Epaminurad placebo

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical

All Listed Sponsors

lead

JW Pharmaceutical

INDUSTRY